GC Medical Science (GCMS) has signed a comprehensive business agreement with GenBody, which specializes in in-vitro diagnosis, for manufacturing technology transfer and production cooperation of the COVID-19 antibody diagnostic kit.
Under the agreement, GCMS plans to carry out export permits and actual export activities starting this month through technology transfers related to the COVID-19 antibody diagnostic kit, the company said on April 13.
The company is currently discussing export contracts with the Swiss healthcare company. It is also targeting South American, African and Southeast Asian markets in the future.
GenBody's COVID-19 antibody diagnostic kit is an immunological product that can be diagnosed within 10 minutes with one or two drops of small blood. A quick on-site diagnosis is possible only with the kit without any additional equipment.
GCMS is planning to contract manufacturing organization (CMO) from GenBody and other companies at the same time through its factory in North Chungcheong Province, which can produce both molecular diagnosis and antibody diagnostic kits.
Previously, GCMS signed a contract with Genecast to develop ultra-sensitive molecular diagnosis kits and also with M Monitor for POCT molecular diagnosis kits that can check for COVID-19 infection within an hour.
Ahn Eun-eok, CEO of GCMS, said, "With this contract, we will establish an integrated platform ranging from the COVID-19 molecular diagnosis to immune diagnosis.
From advanced countries with test infrastructure to developing countries with relatively poor test environments, we will provide optimal diagnostic solutions to various regions around the world."
